Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

The Feinstein Institute for

Neither a doctor nor a teaching hospital

Research payments

$472,878

49 payments

Through program year 2024, The Feinstein Institute for is reported as receiving $472,878 in research payments, across 49 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $128,429 8
2023 Research $68,215 4
2022 Research $108,356 11
2021 Research $3,172 1
2020 Research $31,772 12
2019 Research $132,934 13

Breakdown

Who paid Research payments · program years 2019–2024
  1. AbbVie, Inc. $122,424 7 payments
  2. Penumbra, Inc. $110,357 22 payments
  3. AstraZeneca UK Limited $90,812 6 payments
  4. Alexion Pharmaceuticals, Inc. $76,863 7 payments
  5. Celgene Corporation $50,421 1 payment
  6. AstraZeneca AB $11,568 2 payments
  7. Amgen Inc. $6,005 1 payment
  8. Roche Products Limited $3,928 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $500 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. Complete $72,801 14 payments
  2. Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis $66,697 4 payments
  3. A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease $53,252 3 payments
  4. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cc-220 in Subjects With Active Systemic Lupus Erythematosus (Cc-220-Sle-002) $50,421 1 payment
  5. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) $47,580 2 payments
  6. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) $43,972 2 payments
  7. Surf $28,756 7 payments
  8. This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR and Rad3 related protein kinase and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 in second or third line setting in patients with Triple negative breast cancer prospectively stratified by presence absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway $24,639 1 payment
  9. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $16,687 2 payments
  10. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy $14,185 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record